Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study
Authors:
- Caroline Sindet-PedersenCSCaroline Sindet-Pedersen
- Laila StaerkLSLaila Staerk
- Jannik Langtved PallisgaardJPJannik Langtved Pallisgaard
- Thomas Alexander GerdsTGThomas Alexander Gerds
- Jeffrey S BergerJBJeffrey S Berger
- Christian Torp-PedersenCTChristian Torp-Pedersen
- Gunnar H GislasonGGGunnar H Gislason
- Jonas Bjerring OlesenJOJonas Bjerring Olesen
Open Access
- 26 June 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 4 (4) , 220-227
Abstract
To investigate the risk of all-cause mortality, recurrent VTE, and hospitalized bleeding in patients with VTE treated with either rivaroxaban or apixaban. Using Danish nationwide registries, patients with VTE treated with rivaroxaban or apixaban in the period from January 1st 2015 to June 30th 2017 were identified. Standardized absolute risks were estimated based on outcome-specific Cox regression models, adjusted for potential confounders. A total of 8,187 patients were included in the study, of which 1,504 (18%) were treated with apixaban (50% males, median age 70 years; inter quartile range (IQR) 56-80) and 6,683 (82%) were treated with rivaroxaban (55% males, median age 67 years; IQR 53-76). The 180 days risk of all-cause mortality was 5.08% (95%CI: 4.08% to 6.08%) in the apixaban group and 4.60% (95% CI: 4.13% to 5.18%) in the rivaroxaban group (absolute risk difference: -0.48% (95% CI: -1.49% to 0.72%) The 180 days risk of recurrent VTE was 2.16% (95%CI: 1.49% to 2.88%) in the apixaban group and 2.22% (95% CI: 1.89% to 2.52%) in the rivaroxaban group (absolute risk difference of 0.06% (95% CI: -0.72% to 0.79%)). The 180 days risk of hospitalized bleeding was 1.73% (95%CI: 1.22% to 2.35%) for patients in the apixaban group and 1.89% (95%CI: 1.56% to 2.20%) in the rivaroxaban group (absolute risk difference: 0.16% (95% CI: -0.59% to 0.81%)). In a nationwide cohort of 8,187 patients with VTE treated with rivaroxaban or apixaban there were no significant differences in the risks of all-cause mortality, recurrent VTE, or hospitalized bleeding.Keywords
Funding Information
- The Danish Counsel of Independent Research (4183-00008)
This publication has 23 references indexed in Scilit:
- Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled AnalysisCirculation, 2014
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- The Danish National Patient RegisterScandinavian Journal of Public Health, 2011
- The Danish Civil Registration SystemScandinavian Journal of Public Health, 2011
- The Danish National Prescription RegistryScandinavian Journal of Public Health, 2011
- An automated database case definition for serious bleeding related to oral anticoagulant usePharmacoepidemiology and Drug Safety, 2011
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Marginal Structural Models as a Tool for StandardizationEpidemiology, 2003
- Predictors of Survival After Deep Vein Thrombosis and Pulmonary EmbolismArchives of internal medicine (1960), 1999